Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Decline in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 15,100 shares, a drop of 95.6% from the September 30th total of 346,200 shares. Based on an average trading volume of 196,600 shares, the short-interest ratio is currently 0.1 days. Approximately 0.2% of the company’s shares are short sold.

Estrella Immunopharma Stock Performance

Shares of NASDAQ ESLA traded up $0.05 during trading hours on Friday, hitting $0.90. The company’s stock had a trading volume of 4,190 shares, compared to its average volume of 82,161. Estrella Immunopharma has a 12 month low of $0.77 and a 12 month high of $3.23. The stock has a market cap of $32.74 million, a price-to-earnings ratio of -0.46 and a beta of 0.18. The business has a 50-day simple moving average of $1.05 and a 200-day simple moving average of $1.12.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings data on Friday, September 27th. The company reported ($0.13) earnings per share for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.